Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission. Nobody really looks forward to reading a Hims review. But hair loss comes for us ...

at a much lower price. The company’s Super Bowl ad highlights the high cost of these medications and the need for more affordable options. PSM Accuses Hims & Hers of Misleading Claims PSM argues ...

Compounded GLP-1s are typically much cheaper and can serve as an alternative for patients who are navigating complex supply hurdles and spotty insurance coverage. Hims & Hers sells compounded ...